You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NK1 receptor antagonists,

Showing 1 - 25 of 8,638
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer, Chemo-induced Nausea and Vomiting Trial in Hanzhou (Aprepitant, Palonosetron, Fosaprepitant)

Not yet recruiting
  • Breast Cancer
  • Chemotherapy-induced Nausea and Vomiting
  • Hanzhou, Zhejiang, China
    the Second Affiliated Hospital of Zhejiang Univercity School of
Apr 23, 2023

Primary Aldosteronism Trial in Montréal (Renin measurements)

Not yet recruiting
  • Primary Aldosteronism
  • Renin measurements
  • Montréal, Quebec, Canada
    Hôpital du Sacré-Coeur de Montréal
Oct 30, 2023

Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

Not yet recruiting
  • Synovial Sarcoma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

IL-1ß and Its Receptor Antagonists in Treatment of Severe

Withdrawn
  • Critical Illness
  • Sepsis, Severe
    • (no location specified)
    Jun 13, 2022

    Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

    Not yet recruiting
    • Myeloma
    • Fludarabine phosphate
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 27, 2023

    Gynecologic Cancer Trial in Ann Arbor (Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA))

    Recruiting
    • Gynecologic Cancer
    • Ann Arbor, Michigan
      University of Michigan Rogel Cancer Center
    Jan 6, 2022

    Pediatric Cancer Trial in Yerevan (Ondansetron, Dexamethasone)

    Not yet recruiting
    • Pediatric Cancer
    • Yerevan, Armenia
      Hematology Center named after prof. R. Yeolyan
    May 23, 2023

    Exercise, Histamine Trial in Ghent (Placebo: Placebo + exercise training., H1 blockade: H1 receptor antagonist + exercise

    Active, not recruiting
    • Exercise
    • Histamine
    • Placebo: Placebo + exercise training.
    • +2 more
    • Ghent, Oost-Vlaanderen, Belgium
      Department of movement and sports sciences, Ghent University, Be
    Nov 8, 2022

    Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,

    Recruiting
    • Colorectal Cancer
    • +11 more
    • Cleveland, Ohio
      University Hospitals Cleveland Medical Center, Case Comprehensiv
    Jan 18, 2023

    Chemo Induced Nausea and Vomiting Trial in Mount Olive (Akynzeo)

    Recruiting
    • Chemotherapy Induced Nausea and Vomiting
    • Mount Olive, Alabama
      Rudolph M Navari
    Oct 8, 2023

    Breast Cancer, Tumor, Breast, Breast Diseases Trial in Poland (Sacubitril-valsartan)

    Not yet recruiting
    • Breast Cancer
    • +12 more
    • Opole, Opolskie, Poland
    • +3 more
    Jul 15, 2022

    Prurigo Nodularis Trial in Germany (serlopitant, Placebo)

    Completed
    Has Results
    • Prurigo Nodularis
    • Berlin-Mitte, Germany
    • +14 more
    May 18, 2021

    Lymphoma, Non-Hodgkin, B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma Trial in Australia, United States (NKX019)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • +9 more
    • NKX019
    • Denver, Colorado
    • +6 more
    Jan 19, 2022

    Postoperative Nausea and Vomiting, Anesthesia Complication, Thoracic Diseases Trial (Ondansetron 8mg, Fosaprepitant 150 mg)

    Not yet recruiting
    • Postoperative Nausea and Vomiting
    • +2 more
    • Ondansetron 8mg
    • Fosaprepitant 150 mg
    • (no location specified)
    Jun 4, 2023

    Relapsed/Refractory AML, AML, Adult, MDS Trial in United States (NKX101 - CAR NK cell therapy)

    Recruiting
    • Relapsed/Refractory AML
    • +3 more
    • NKX101 - CAR NK cell therapy
    • Denver, Colorado
    • +6 more
    Apr 8, 2022

    Implication of 5-HT7 Receptor in Inflammatory Mechanisms in

    Not yet recruiting
    • Healthy
    • Multiple Sclerosis
    • Blood sample
    • Orléans, France
      CHR Orléans
    Feb 16, 2023

    Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell

    Recruiting
    • Recurrent Adult T-Cell Leukemia/Lymphoma
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Nov 18, 2022

    Cervical Cancer, Chemo Effect, Programmed Cell Death 1 Receptor / Antagonists & Inhibitors Trial (Sindilimab +paclitaxel+

    Not yet recruiting
    • Cervical Cancer
    • +3 more
    • Sindilimab +paclitaxel+ cisplantin
    • (no location specified)
    Mar 14, 2021

    Renin Angiotensin Aldosterone System Genetic Polymorphism on

    Recruiting
    • Myocardial Infarction
      • Cairo, Egypt
        Ain Shams University
      May 16, 2023

      Chemo-induced Nausea and Vomiting Trial in Zhuhai (Olanzapine+NK-1 RA+5-HT3 RA, Dexamethasone+NK-1 RA+5-HT3 RA)

      Recruiting
      • Chemotherapy-induced Nausea and Vomiting
      • Olanzapine+NK-1 RA+5-HT3 RA
      • Dexamethasone+NK-1 RA+5-HT3 RA
      • Zhuhai, Guangdong, China
        Fifth Affilliated Hospital of Sun Yat-sen University
      May 17, 2021

      Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

      Active, not recruiting
      • Adult Grade III Lymphomatoid Granulomatosis
      • +23 more
      • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
      • +2 more
      • Duarte, California
        City of Hope Medical Center
      Jan 4, 2023

      Heart Failure Trial (Finerenone, Placebo)

      Not yet recruiting
      • Heart Failure
      • (no location specified)
      Sep 11, 2023

      Chemo-induced Nausea and Vomiting (CINV) Trial in Shanghai (Granisetron Transdermal Delivery System)

      Recruiting
      • Chemotherapy-induced Nausea and Vomiting (CINV)
      • Granisetron Transdermal Delivery System
      • Shanghai, China
        Fudan University Shanghai Cancer Center
      Apr 19, 2022

      Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus Trial in Lahore (NK-1R antagonist)

      Unknown status
      • Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus
      • NK-1R antagonist
      • Lahore, Punjab, Pakistan
        Bahria International Hospital
      Jul 10, 2020

      Breast Cancer With or Without BRCA Mutation

      Recruiting
      • Breast Cancer
      • Androgen receptor status and BRCA mutation
      • Varanasi, UP, India
        Banaras Hindu University
      Jun 2, 2022